19,073 Shares in Edwards Lifesciences Corporation $EW Acquired by Fideuram Intesa Sanpaolo Private Banking S.P.A.

Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new position in Edwards Lifesciences Corporation (NYSE:EW) during the 4th quarter, HoldingsChannel reports. The fund acquired 19,073 shares of the medical research company’s stock, valued at approximately $1,626,000.

Several other hedge funds have also bought and sold shares of the stock. Vanguard Group Inc. lifted its position in shares of Edwards Lifesciences by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company’s stock valued at $5,472,147,000 after buying an additional 365,581 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Edwards Lifesciences by 4.9% during the 3rd quarter. Wellington Management Group LLP now owns 20,804,416 shares of the medical research company’s stock valued at $1,617,959,000 after buying an additional 977,933 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Edwards Lifesciences by 8.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock valued at $1,478,425,000 after buying an additional 1,423,365 shares in the last quarter. Jennison Associates LLC lifted its position in shares of Edwards Lifesciences by 19.6% during the 3rd quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock valued at $1,085,574,000 after buying an additional 2,287,783 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Edwards Lifesciences by 278.3% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock valued at $434,318,000 after buying an additional 4,108,270 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 620 shares of the firm’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $81.14, for a total value of $50,306.80. Following the completion of the sale, the vice president directly owned 40,411 shares of the company’s stock, valued at $3,278,948.54. This trade represents a 1.51% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott B. Ullem sold 13,000 shares of the firm’s stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $80.04, for a total value of $1,040,520.00. Following the completion of the sale, the chief financial officer directly owned 39,699 shares of the company’s stock, valued at $3,177,507.96. This trade represents a 24.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 106,684 shares of company stock valued at $8,811,739 in the last three months. 0.31% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

EW has been the subject of several recent research reports. Mizuho set a $95.00 price objective on Edwards Lifesciences and gave the company an “outperform” rating in a research note on Monday, April 13th. BTIG Research increased their price objective on Edwards Lifesciences from $98.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, April 24th. Canaccord Genuity Group set a $85.00 price objective on Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Monday, April 20th. Finally, Wolfe Research raised Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price objective for the company in a research note on Wednesday, April 1st. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $95.65.

Edwards Lifesciences Stock Up 0.3%

NYSE EW opened at $83.24 on Friday. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $87.89. The company has a market cap of $47.93 billion, a P/E ratio of 44.27, a P/E/G ratio of 2.08 and a beta of 0.87. The business has a fifty day moving average price of $81.41 and a 200 day moving average price of $82.87. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The business had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. During the same period last year, the company earned $0.64 EPS. The company’s revenue for the quarter was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Research analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.